Hims & Hers Health (NYSE:HIMS) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Hims & Hers Health (NYSE:HIMS) posted its earnings results on Monday. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02, Zacks reports. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health updated its Q1 2025 guidance to EPS and its FY 2025 guidance to EPS.

Hims & Hers Health Trading Up 4.2 %

NYSE:HIMS opened at $51.37 on Tuesday. Hims & Hers Health has a 1 year low of $9.67 and a 1 year high of $72.98. The stock has a market cap of $11.22 billion, a price-to-earnings ratio of 116.75 and a beta of 1.35. The stock has a 50-day moving average price of $35.45 and a two-hundred day moving average price of $26.08.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 4,152 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the completion of the transaction, the insider now directly owns 157,345 shares of the company’s stock, valued at approximately $9,549,268.05. The trade was a 2.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 128,127 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total value of $7,465,960.29. Following the transaction, the chief executive officer now directly owns 97,687 shares of the company’s stock, valued at $5,692,221.49. This represents a 56.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,080,275 shares of company stock valued at $37,247,354. Company insiders own 17.71% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on HIMS shares. Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. BTIG Research started coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. Piper Sandler lifted their price objective on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Monday, January 6th. Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Finally, Morgan Stanley downgraded Hims & Hers Health from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $28.53.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.